Concert Pharmaceuticals – pharmaceutical daily

September 17, 2019 Off

Concert Pharmaceuticals Completes Enrollment in Second Open Label Trial of CTP-543 to Evaluate Once-Daily vs. Twice-Daily Dosing in Patients with Alopecia Areata

LEXINGTON, Mass.–(BUSINESS WIRE)–$CNCE #Aim2TreatAlopeciaAreata—Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment of an open label…

May 16, 2019 Off

Concert Pharmaceuticals Announces Initiation of New Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata

By BusinessWire

LEXINGTON, Mass.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24CNCE&src=ctag" target="_blank"gt;$CNCElt;/agt; lt;a href="https://twitter.com/hashtag/CNCE?src=hash" target="_blank"gt;#CNCElt;/agt;–Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated a second…